Research
Energy balance
The safety profile of tirzepatide is consistent across all phase 3 trials.
Practitioners can expect a consistent safety profile when prescribing tirzepatide.
StrongSupportsmedium confidence
The safety profile of tirzepatide is consistent across all phase 3 trials.
Why this rating
Based on phase 3 trials mentioned in the abstract.
Source
A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health
John D. Bucheit et al. · Journal of Cardiovascular Pharmacology · 2022
DOI 10.1097/fjc.0000000000001299
reviewCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →